Ann: Phase II TACTI-002 trial recruitment successfully completed, page-82

Yes, I like the way Imugene, PTX and Chimeric present themselves. Immutep could learn a thing or two by analyzing their PR approach and language and strategies.
While results are everything in biotech, the share price and mkt cap is a big factor in what capital resources, talent and connections you can attract, which all helps in getting results and advancing the project.

I’m not saying they are doing a bad job, I like that we are a grounded no BS results driven company doing fantastic work. But there is no denying that our results, stage of development and pipeline should be valued higher by the market, imo. We should be sitting at around $750-1Bil min. Now maybe that will happen within the next 6 months anyway, I hope so. But management I hope are looking at the marketing and PR side and asking. Are we doing everything right? Can we improve on how we are selling this company?